Update as of 10 October 2024 : Since the public consultation and appeals period for the HTA Council Preliminary Recommendation on Citicoline for Ischemic Stroke ended on 09 October 2024 without appeals received, this preliminary HTA Council recommendation lapsed into the Final Recommendation and was transmitted to the Secretary of Health for decision. Published 25 continue reading : HTA Council Preliminary Recommendation on Citicoline For Ischemic Stroke
Insulin Glargine and Insulin Detemir for Type 1 and Type 2 Diabetes Mellitus
On 10 October 2022, the OIC-Secretary of Health (SOH) approved the Health Technology Assessment Council (HTAC) recommendation for the government financing of both insulin glargine 10mL vial (100 IU/ml) and 3mL pre-filled pen (100 IU/ml) for patients with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) through their inclusion in the Philippine National Formulary (PNF). In continue reading : Insulin Glargine and Insulin Detemir for Type 1 and Type 2 Diabetes Mellitus
Rituximab for the Treatment of Non-Hodgkin’s Lymphoma
Date of publication: 29 July 2022 Approval of the Secretary of health: 31 August 2022 Link to the Evidence summary HTAC Recommendation preview:
Insulin glargine (100 IU/mL, 10 mL vial and 3 mL pre-filled pen) for Type 1 and Type 2 Diabetes Mellitus
Preliminary Recommendation for the Inclusion of Insulin Glargine and Insulin Detemir for Type 1 and Type 2 Diabetes Mellitus in the PNF Link to the Evidence Summary: Evidence Summary on insulin glargine and detemir for type 1 and type 2 diabetes mellitus Link to appeals form here: https://hta.doh.gov.ph/topic-nomination/ (stakeholders may submit appeals to hta@doh.gov.ph until 11 August 2022.) Document Preview: